ArticleNPJ digital medicine2026
Instant messaging-delivered brief motivational interviewing for noncommunicable disease patients with no intention to quit smoking.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Most noncommunicable disease patients who continue smoking are chronic users with no intention to quit. This multicentre randomised controlled trial evaluated the effectiveness of brief motivational interviewing (MI) delivered using mobile instant messaging on smoking abstinence in this population. Overall, 728 adults were recruited and randomised (1:1) to the intervention or control group. Intervention group received a face-to-face brief MI session followed by instant messaging-delivered brief MI for 6 months. Control group received a face-to-face health advice consultation and a self-help booklet. Follow-ups were conducted at 3, 6, and 12 months. The primary outcome was biochemically validated smoking abstinence at 12 months, defined as self-reported abstinence from smoking in the last 7 days confirmed by exhaled carbon monoxide <4 ppm and saliva cotinine <15 ng/mL. At 12 months, 4.1% of participants in the intervention group met the primary outcome, compared with 1.4% in the control group (rate ratio [RR], 3.00; 95% confidence interval [CI], 1.10-8.17; P = 0.03). Secondary outcomes were also significantly higher in the intervention group, including validated abstinence at 6 months (4.7% vs 1.4%; RR, 3.40; 95% CI, 1.27-9.12; P = 0.02) and intention to quit at both 3 months (30.8% vs 18.9%; RR, 1.63; 95% CI, 1.25-2.13; P < 0.001) and 6 months (33.7% vs 24.1%; RR, 1.40; 95% CI, 1.10-1.79; P = 0.01). The intervention could be easily integrated into existing smoking cessation services, effectively motivating individuals who had no intention of quitting to quit-addressing one of the major challenges in tobacco control.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.